Atlas Trials

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Clinical trial NCT06685757 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06685757
Sponsor
Biogen
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Antibody-mediated Rejection
Start date
2024-12-03
Primary completion
2026-12-01
Enrollment
132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.